Evidence map›Paper›PMID 32687658›Full record

ArticleThe Prostate2020

Identifying and treating ROBO1

Marina G Ferrari, Arsheed A Ganaie, Ashraf Shabenah, Adrian P Mansini, Li Wang, Paari Murugan, Elai Davicioni, Jinhua Wang, Yibin Deng, Luke H Hoeppner and 3 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Prostate, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.6field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 2 countries.

Marina G FerrariDepartment of Urology, University of Minnesota, Minneapolis, Minnesota.
Arsheed A GanaieDepartment of Urology, University of Minnesota, Minneapolis, Minnesota.
Ashraf ShabenahMasonic Cancer Center, Institute for Health Informatics, University of Minnesota, Minneapolis, Minnesota.
Adrian P MansiniDepartment of Urology, University of Minnesota, Minneapolis, Minnesota.
Li WangSection of Cancer Biology, Hormel Institute, University of Minnesota, Austin, Minnesota.
Paari MuruganDepartment of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota.
Elai DavicioniDecipher Biosciences, Inc, San Diego, California.
Jinhua WangMasonic Cancer Center, Institute for Health Informatics, University of Minnesota, Minneapolis, Minnesota.
Yibin DengDepartment of Urology, University of Minnesota, Minneapolis, Minnesota.
Luke H HoeppnerSection of Cancer Biology, Hormel Institute, University of Minnesota, Austin, Minnesota.
Christopher A WarlickDepartment of Urology, University of Minnesota, Minneapolis, Minnesota.
Badrinath R KonetyDepartment of Urology, University of Minnesota, Minneapolis, Minnesota.
Mohammad SaleemDepartment of Urology, University of Minnesota, Minneapolis, Minnesota.ORCID 0000-0002-7422-7967
University of Minnesota · USCoherus BioSciences (United States) · US

Funding

University of Minnesota Clinical and Translational Science Institute (UMN CTSI)UL1TR002494 · NCATS · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R, WEISDORF, DANIEL J · 2018 to 2022
$34.9M
Research CoreU54MD008620 · NIMHD · UNIVERSITY OF MINNESOTA · PI BRADY, SONYA S, SHIKANY, JAMES M · 2013 to 2017
$13.5M
Novel targeted chemo/immunotherapy approach for localized and metastatic CaPR01CA193739 · NCI · UNIVERSITY OF MINNESOTA · PI BHAT, MOHAMMAD SALEEM · 2016 to 2020
$1.8M
Novel gene that determines metastatic phenotype in African-American men with PCaR21CA184685 · NCI · UNIVERSITY OF MINNESOTA · PI BHAT, MOHAMMAD SALEEM · 2015 to 2016
$582k
NCI NIH HHS CA184685NCI NIH HHS CA193739NCI NIH HHS R01 CA193739NCI NIH HHS R21 CA184685NIMHD NIH HHS U54 MD008620NIMHD NIH HHS U54MD008620
6 · The paper itself

Abstract

backgroundThere is a need to develop novel therapies which could be beneficial to patients with prostate cancer (CaP) including those who are predisposed to poor outcome, such as African-Americans. This study investigates the role of ROBO1-pathway in predicting outcome and race-based disparity in patients with CaP. METHODS AND

resultsAided by RNA sequencing-based DECIPHER-testing and immunohistochemical (IHC) analysis of tumors we show that ROBO1 is lost during the progressive stages of CaP, a prevalent feature in African-Americans. We show that the loss of ROBO1 predicts high-risk of recurrence, metastasis and poor outcome of androgen-deprivation therapy in radical prostatectomy-treated patients. These data identified an aggressive ROBO1

conclusionWe suggest that ROBO1 status forms as predictive biomarker of outcome in high-risk populations such as African-Americans and DOCK1-targeting therapy has a clinical potential for treating metastatic-CaP.

Indexed as

AnimalsBlack or African AmericanCell Line, TumorDNA MethylationHealth Status DisparitiesHumansImmunohistochemistryMaleNeoplasm MetastasisNerve Tissue ProteinsPromoter Regions, GeneticProstatectomyProstatic Neoplasmsrac1 GTP-Binding Proteinrac GTP-Binding ProteinsReceptors, ImmunologicDOCK1 protein, humanNerve Tissue Proteinsrac1 GTP-Binding ProteinRAC1 protein, humanrac GTP-Binding ProteinsReceptors, ImmunologicRoundabout ProteinsAfrican AmericanDECIPHERDOCK1prostate cancerROBO1

Identifiers

PMID32687658
PMCPMC7556361
OpenAlexW3044809055

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.